Deep venous thromboses following sclerotherapy are very rare, yet occur more frequently in thrombophilic patients. We have here described two cases in which post-sclerotherapy deep venous thrombosis revealed a mutation in the prothrombin gene (Factor II). We have further explained the principles of sclerotherapy with lauromacrogol (polidocanol). We have finally summarized the causes of thrombophilia and provided practical recommendations regarding sclerotherapy in thrombophilic patients.
Sclerosis, telangiectasia, lauromacrogol, polidocanol, DVT (deep venous thrombosis), thrombophilia, prothrombin gene mutation.
What is already known about the topic?
Thromboembolic events and especially deep venous thromboses following sclerotherapy are rare and probably underdiagnosed.
What does this article bring up for us?
This article recalls the indications of lauromacrogol (polidocanol) and the causes of thrombophilia, along with their frequency. It also summarizes the diagnostic and therapeutic steps for sclerosis, and more particularly in thrombophilia cases